Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

ceftolozane 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Meropenem 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Other Infectious Diseases × Clear all
NCT03485950 2022-03-15

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 33 charts

Other Infectious Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡